Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye d... LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.16 | -4.39727065959 | 26.38 | 26.67 | 23.92 | 96107 | 25.03606813 | CS |
| 4 | 2.58 | 11.3957597173 | 22.64 | 27.46 | 22.34 | 112508 | 24.96644441 | CS |
| 12 | -9.46 | -27.2779700115 | 34.68 | 38.77 | 21.34 | 142330 | 28.89903389 | CS |
| 26 | 1.71 | 7.27350063803 | 23.51 | 38.93 | 19.9001 | 154265 | 27.09337276 | CS |
| 52 | 9.24 | 57.8222778473 | 15.98 | 38.93 | 14.42 | 157501 | 23.21542685 | CS |
| 156 | 9.24 | 57.8222778473 | 15.98 | 38.93 | 14.42 | 157501 | 23.21542685 | CS |
| 260 | 9.24 | 57.8222778473 | 15.98 | 38.93 | 14.42 | 157501 | 23.21542685 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
